COHEREX-EU:A Multi-Center Study to Evaluate the Safety and Efficacy of the Coherex FlatStent Patent Foramen Ovale(PFO) Closure System
A Feasibility study of 50 patients with symptomatic Patent ForamenOvale (PFO) undergoing closure of the defect using the Coherex FlatStent Patent Foramen Ovale (PFO) Closure System to evaluate the Safety and Efficacy of the device.
Coherex Medical Inc.
50 participants
Oct 1, 2007
Interventional
Conditions
Summary
The COHEREX-EU Study is a multi-center registry of the first 50 patients to have their Patent Foramen Ovale closed with the Coheres FlatStent Patent Foramen Ovale (PFO) Closure System. This study will demonstrate the safety and efficacy of the Coheres FlatStent Patent Foramen Ovale (PFO) Closure System.
Eligibility
Plain Language Summary
Simplified for easier understanding
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The Coherex FlatStent Patent Foramen Ovale (PFO) Closure System is a implant placed percutaneously by an interventional cardioligist into a patent foramen ovale to close the congenital defect. Patients will be observed for 6 months post intervention.
Locations(2)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12607000623493